Starting low-dose buprenorphine treatment for people using fentanyl
Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanyl
This study is looking at a new way to start treatment with buprenorphine for people struggling with opioid use disorder, especially those using fentanyl, to see if a low-dose method can help them avoid painful withdrawal symptoms and make it easier for them to get the help they need.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10907800 on NIH RePORTER |
What this research studies
This research investigates a new method for initiating buprenorphine treatment for individuals with opioid use disorder (OUD) who have been using fentanyl. The study aims to determine the safety and effectiveness of a low-dose approach that avoids the painful withdrawal symptoms typically associated with starting treatment. Participants will be randomly assigned to either a standard initiation method or a novel micro-dose method, with the goal of making treatment more accessible and acceptable. The research will involve 60 subjects recruited from the University of Pennsylvania's Center for the Studies of Addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with untreated opioid use disorder who have recently used fentanyl.
Not a fit: Patients who are not currently using opioids or those who have already initiated treatment with buprenorphine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less painful way for individuals with OUD to start treatment, potentially leading to better recovery outcomes.
How similar studies have performed: Other research has shown promise in using low-dose approaches for opioid treatment, but this specific method is relatively novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kampman, Kyle Matthew — University of Pennsylvania
- Study coordinator: Kampman, Kyle Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.